GlobeNewsWire · CLDX · November 19, 2026Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic DermatitisGet the app for moreExplore stock news, insights and company research.Get the app →Source: GlobeNewsWire ↗